Market Overview

The global Hemostats Market size was valued at USD 3.70 Billion in 2024 and is expected to reach USD 6.11 Billion by 2033. The market is projected to grow at a CAGR of 5.44% during the forecast period from 2025 to 2033. Increasing surgical procedures, advancements in hemostatic technologies, and expanding healthcare infrastructure globally are key factors driving this growth.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Hemostats Market Key Takeaways

• Current Market Size: USD 3.70 Billion in 2024
• CAGR: 5.44% during 2025-2033
• Forecast Period: 2025-2033
• North America dominates with a 52.2% market share in 2024 due to advanced healthcare infrastructure and high surgical volume.
• The rise in complex surgeries and trauma cases globally necessitates effective blood loss management solutions.
• Increasing adoption of minimally invasive surgeries and innovations in faster acting and bioabsorbable hemostatic agents supports market growth.
• Growing healthcare infrastructure in emerging economies and enhanced awareness among healthcare professionals also contribute to expansion.
• The elderly population increase, especially in the US, further fuels demand for hemostats in surgical interventions.

Request to Get the Sample Report: https://www.imarcgroup.com/hemostats-market/requestsample

Market Growth Factors

1. Increasing Surgical Procedures:

The global hemostats market is driven significantly by the rising number of surgical procedures worldwide. Annually, approximately 310 million major surgeries occur globally, with the US and Europe accounting for about 40 to 50 million and 20 million surgeries respectively. About 53% of these surgeries are performed on patients over 65 years, who are more vulnerable to age-related diseases necessitating surgical care. This demographic shift is increasing surgical volume, elevating the demand for effective intraoperative blood management tools like hemostats that facilitate rapid wound healing and reduce operative risks.

2. Technological Advancements in Hemostatic Products:

Technological innovation has been pivotal in expanding the hemostats market. Modern hemostats incorporate biocompatible and bioabsorbable materials, reducing adverse reactions and improving safety profiles. Leading companies are investing heavily in R&D to launch next-generation products with enhanced efficacy, ease of application, and adaptability to both open and minimally invasive surgeries. For example, Ethicon’s ETHIZIA Hemostatic Sealing Patch features a synthetic polymer technology that ensures sustained hemostasis in difficult bleeding scenarios, exemplifying advancements driving market adoption.

3. Increasing Prevalence of Chronic Blood Disorders:

The growing incidence of chronic blood disorders globally supports market demand. For instance, 347,026 people were affected by bleeding disorders in 2020, with around 10 million new cases of venous thromboembolism annually worldwide. Europe records about 544,000 deaths related to deep vein thrombosis each year, while the US experiences approximately 900,000 cases of blood clots annually, causing significant mortality. These large patient populations require timely diagnosis and surgical interventions employing effective hemostatic agents, thereby augmenting market growth prospects.

Market Segmentation

By Product:

• Thrombin Based
• Combination Based
• Oxidized Regenerated Cellulose Based
• Gelatin Based
• Collagen Based

Oxidized regenerated cellulose (ORC) based products led the market in 2024 with a 27.0% share, valued for their good hemostatic properties, absorbability, biocompatibility, and wide application including minimally invasive surgeries.

By Application:

• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Others

Orthopedic surgery holds the largest share of 28.2% in 2024, driven by musculoskeletal trauma, fractures, and degenerative bone disorders necessitating surgeries where hemostatic agents control significant intraoperative blood loss.

By Formulation:

• Matrix and Gel Hemostats
• Sheet and Pad Hemostats
• Sponge Hemostats
• Powder Hemostats

Matrix and gel hemostats are the leading formulation with a 40.3% market share in 2024, favored for their versatility, quick action, user-friendliness, and applicability to complex bleeding sites in various surgeries.

Regional Insights

North America dominates the hemostats market with over 52.2% share in 2024, attributed to its advanced healthcare infrastructure, high volume of surgeries, favorable reimbursement policies, and rapid adoption of innovative hemostatic products. The United States alone accounts for approximately 86.2% of this share in the region, driven by the high number of surgeries, particularly orthopedic and cardiovascular, and increasing elderly population.

Recent Developments & News

• April 2025: Baxter International Inc. launched Hemopatch Sealing Hemostat with room temperature storage, enhancing surgical accessibility in Europe.
• April 2025: A patent was granted to a research team from Banaras Hindu University and IIT BHU for a hemostatic patch using homogeneous polymer and Ayurvedic medication via nanotechnology.
• January 2025: Cresilon Inc. commercialized TRAUMAGEL, a plant-based hemostatic gel in the US, stopping bleeding rapidly at point of care.
• September 2024: BC3 Technologies partnered with First Aid Only to distribute SEAL Hemostatic Spray, the first aerosolized chitosan for managing critical arterial bleeding.
• August 2024: Pakistan patented the world's first hemostat dressing made from biopolymer chitosan derived from marine life, capable of rapid bleeding control.

Key Players

• Advanced Medical Solutions Group PLC
• B. Braun SE
• Baxter International Inc.
• Becton, Dickinson and Company
• Hemostasis, LLC
• Johnson & Johnson MedTech
• Medtronic PLC
• Pfizer Inc.
• Stryker Corporation
• Teleflex Incorporated

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=2381&flag=C

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302